Clinical Trial

R21/Matrix-M in African Children Against Clinical Malaria

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Phase III randomized controlled multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-01-07; most recent amendment 2026-02-20.
Status change: Enrolling by Invitation → Active, Not Recruiting 2022-01-26
Status change: Not Yet Recruiting → Enrolling by Invitation 2021-05-20
Trial Details
NCT Number NCT04704830
Lead Sponsor University of Oxford
Collaborators: Institut de Recherche en Sciences de la Sante, Burkina Faso, Institut de Recherche en Sciences de la Sante-Direction Regionale de l'Ouest, Malaria Research and Training Center, Bamako, Mali, KEMRI-Wellcome Trust Collaborative Research Program, Ifakara Health Institute Clinical Trial Facility, Bagamoyo Research and Training Centre, PO Box 74, Bagamoyo, Tanzania, London School of Hygiene and Tropical Medicine
Conditions Malaria
Enrollment 4,800 participants
Start Date 2021-04-29
Primary Completion 2023-03-21 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-23